(Q24246163)

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

Amelioration of negative symptoms in schizophrenia by glycine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

D-serine added to antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

Clinical and sensorimotor gating effects of ketamine in normals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

METHIONINE EFFECTS ON CHRONIC SCHIZOPHRENICS: PATIENTS TREATED WITH MONOAMINE OXIDASE INHIBITORS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

A clinical trial of monosodium glutamate (1-glutavite(R)) on hospitalized elderly male psychotic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

Negative symptoms in schizophrenia. Definition and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

The unit of analysis error in studies about physicians' patient care behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

Issues in the meta-analysis of cluster randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

The emerging role of glutamate in the pathophysiology and treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

Treatment of negative and cognitive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

A separate disease within the syndrome of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

Understanding controlled trials. Crossover trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

D-amino acids as putative neurotransmitters: focus on D-serine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

Glutamatergic mechanisms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

Neurobiology through the looking-glass: D-serine as a new glial-derived transmitter

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

7 January 2021

Glycine therapy of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

7 January 2021

Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

7 January 2021

d-Cycloserine therapy of psychosis by symptom provocation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

7 January 2021

Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

7 January 2021

A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

7 January 2021

D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

7 January 2021

Adjunctive high-dose glycine in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

7 January 2021

Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

7 January 2021

A preliminary study of the effects of glutamic acid on catatonic schizophrenics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

7 January 2021

Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

7 January 2021

D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

7 January 2021

An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

7 January 2021

Some behavioral effects associated with feeding sodium glutamate to patients with psychiatric disorders

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

7 January 2021

The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale. Reliability, comparability, and predictive validity.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

7 January 2021

Five-factor model of schizophrenia. Initial validation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

7 January 2021

Pharmacological augmentation of NMDA receptor function for treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

7 January 2021

Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

7 January 2021

D-cycloserine added to clozapine for patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

7 January 2021

Placebo-controlled trial of glycine added to clozapine in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003730.PUB2

7 January 2021

10.1002/14651858.CD003730.PUB2

Identifiers

DOI

0 references

Fatcat ID

release_54xzg6tef5f3bh774u6xyheawu

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/54xzg6tef5f3bh774u6xyheawu

24 November 2022